Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ICMT | O60725 | 2/20 | 0.35 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | LIG1 | P18858 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | JAK3 | P52333 | 1/20 | 0.31 |
| ▸ | BTK | Q06187 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22799633 | 0.86 | LIG1 (0.44) | LIG1TDP1LMNAKDM4EMEN1 | |
| SCHEMBL22800223 | 0.84 | ICMT (0.36) | ICMTCAPN1L3MBTL1LIG1TDP1 | |
| SCHEMBL22800072 | 0.83 | CAPN1 (0.34) | ICMTCAPN1LIG1TDP1KDM4E | |
| SCHEMBL22800780 | 0.82 | ICMT (0.37) | ICMTCAPN1TDP1JAK3BTK | |
| SCHEMBL22800166 | 0.80 | L3MBTL1 (0.36) | ICMTCAPN1L3MBTL1LIG1TDP1 | |
| SCHEMBL22799632 | 0.80 | ICMT (0.35) | ICMTCAPN1L3MBTL1LIG1TDP1 | |
| SCHEMBL22799765 | 0.79 | MAPT (0.35) | TDP1JAK3BTKLMNAUTS2R | |
| SCHEMBL22799780 | 0.79 | CAPN1 (0.36) | ICMTCAPN1KMT2A | |
| SCHEMBL22800153 | 0.79 | PTGER4 (0.34) | CAPN1KMT2A | |
| SCHEMBL22799659 | 0.75 | ALDH1A1 (0.48) | LIG1CYP3A4LMNAKDM4EHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200392157-A1 | CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF | Knobbe, Martens, Olson & Bear, LLP | 2020-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200392157-A1 | CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF | CAPNS1, CAPN2, CAPN1 | ICMT 4672/4885CAPN1 3/4885L3MBTL1 3891/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.